Grünenthal, a leading pharmaceutical company specializing in pain research and management, has announced a significant investment of over €80 million in its Latin American production sites. These investments will modernize and expand Grünenthal’s production capabilities, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond.
The investments include the complete refurbishment of a 3,500-square-meter solids plant in Santiago de Chile, creating a world-class manufacturing facility with an annual production capacity of 1.8 billion tablets. In addition, a new 1,800-square-meter plant in Quito, Ecuador, will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.
According to Victor Barbosa, Head of Global Operations and member of the Executive Board Team, this investment is a strong demonstration of Grünenthal’s commitment to long-term competitiveness in the region. “Future-proofing our manufacturing capabilities underscores our commitment to ensuring a safe, reliable, and efficient supply of medicine to patients globally. Grünenthal delivers high-quality medicine from Latin America to the world—a unique capability in the region,” Barbosa explains.
Grünenthal has been operating in Santiago de Chile for 45 years and is the country’s leading pharmaceutical manufacturer. The new investment in Chile is the company’s largest in the past three decades, and the state-of-the-art technology will not only enhance production capabilities but also provide employees with training and specialization opportunities.
In addition, Grünenthal’s manufacturing site in Quito, Ecuador, is one of the few in Latin America licensed to export to Europe and the only one in Ecuador with an EU Good Manufacturing Practice certificate. The 50,000-square-meter campus is the largest and most modern manufacturing plant for pharmaceuticals in Ecuador and will produce high-quality tablets for European pain patients starting in 2025.
Grünenthal is a global leader in pain management and related diseases and is headquartered in Aachen, Germany. The company has affiliates in 27 countries across Europe, Latin America, and the U.S. and employs around 4,400 people. Its products are available in approximately 100 countries, and in 2023, Grünenthal achieved revenues of €1.8 billion.
For more information about Grünenthal, please visit https://www.grunenthal.com and Grünenthal Report 2023/24.
Follow Grünenthal on LinkedIn and Instagram for the latest updates and news. For media inquiries, please contact Jessica Liu, Global Corporate Affairs & Communication, at jessica.liu@grunenthal.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.